Novogen to Present at Bio International Convention Philadelphia 2015

SYDNEY, June 12, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced today that Novogen Group CEO, Graham Kelly, will be presenting at the Bio International Convention 2015 (BIO) being held at the Pennsylvania Convention Centre, 1101 Arch St, Philadelphia, PA 19107.

Details of the Novogen presentation are as follows:

Presentation Date: Tuesday, June 16
Presentation Time: 9:45 AM
Presentation Room: Theater 4, "The Incredible Helix"
BIO Presentation Track: Oncology
Social Media: #BIO2015

The presentation will provide an update on the Company's oncology pipeline of three drug candidates, Cantrixil, TRXE-009 and Anisina, and their timetables and clinical strategies. The Company also is scheduled to present to a range of investor conferences being held in Philadelphia in conjunction with BIO, as well as meeting with a wide range of companies seeking business development opportunities with Novogen and its subsidiary, CanTx Inc.

About BIO

BIO is the world's largest biotechnology gathering, allowing companies to reach influential decision-makers who come to discover new players in the industry, hold meetings and evaluate emerging technologies.

Last year BIO 2014 hosted almost 16,000 industry leaders, including nearly 2,500 CEOs. Attendees came from thousands of organisations including the world's foremost biotech companies and more than 300 academic institutions including major research laboratories and government agencies from around the world, as well as the industry's leading consultants and service companies.

About Novogen

Novogen is a public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University. Novogen has two drug technology platforms yielding drug candidates that are first-in-class with potential application across a broad range of degenerative diseases. In the oncology field, the ultimate objective is to see both drug technologies used in combination as first-line therapy across most forms of cancer, with the objective of preventing tumor recurrence. This objective is based on a strategy of achieving comprehensive destruction of the full hierarchy of cells within a tumor with the super-benzopyran technology platform killing the tumor-initiating cells and the anti-tropomyosin technology, combined with vinca alkaloids, to deliver a potent chemical debulking effect on their daughter cells.

For more information, please visit www.novogen.com